SOLICITATION NOTICE
A -- Measure Levels of Estradiol, Progesterone, Testosterone, Sex Hormone
- Notice Date
- 8/20/2009
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-90201-MM
- Archive Date
- 9/18/2009
- Point of Contact
- Melissa P Marino, Phone: 301-402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
marinome@mail.nih.gov, cr214i@nih.gov
(marinome@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), plans to procure on a sole source basis with Quest Diagnostics Nichols Institute, 14225 Newbrook Drive, Chantilly, VA 20153. The contractor shall measure levels of estradiol, progesterone, testosterone, sex hormone bringing globulin and follicle stimulating hormone in serum samples of cases enrolled in the Polish Breast Cancer Case-Control Study. The North American Industry Classification System Code is 541712 and the business size standard in 500 employees. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). NCI is currently using image analysis to quantitatively assess levels of ER, PR, HER2, EGFR, Cytokeratin 5, and Aromatase in terminal duct lobular units (TDLUs) associated with 395 breast cancers in the Polish study. These TDLUs were taken at different distances from invasive tumors, prepared as tissue microarrays, and are currently being marked for automated analysis with the Aperio system. In addition, NCI will review H&E stained whole sections from these cases to characterize the level of involution in these TDLUs. NCI would like to correlate serum hormone levels with tissue receptor expression, lobular involution, and assess multivariate relationships using risk factor data collected via interview as covariates. NCI also wishes to evaluate case-control associations with serum hormone levels in this study subset. The objective of this procurement is to measure levels of Estradiol, Progesterone, Testosterone, Sex hormone binding globulin (SHBG), and Follicle stimulating hormone (FSH) in serum samples of 395 breast cancer cases and 395 controls enrolled in the Polish breast cancer case-control study. Findings from this study may enhance NCI's understanding of hormonal etiology of breast cancer. Contractor Requirements The vendor shall: 1.Measure levels of hormones in serum samples of 395 cases and 395 controls using an immunoassay; 2.Include 51 blinded duplicate samples to assess batch variation; 3.Deliver raw and processed data in an Excel file; 4.Provide technical guidance and trouble shooting to the NCI Project Officer on the work performed under this procurement. Quest Diagnostics Nichols Institute offers the test for sex hormone measurement with diagnosis-level quality. The company routinely performs serum hormone measurement on a daily basis, with the capacity to handle large number of samples and a fast turn-around time. Most importantly, NCI used its service to measure hormones in several other Polish projects and using same service for this project will ensure the comparability of the results across our studies, which is a critical component of the study. Quest Diagnostics possesses the unique feature that fits NCI's study design. A highly reliable and timely service is the key for this project to correlate serum hormone levels with tumor marker expression in normal TDLUs identified in breast cancer cases and risk factor data. This is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the researcher to determine if the party can perform this requirement. An original and one copy of the capability statement must be received in the contracting office on or before 11:00 am ET on September 3, 2009 to Melissa Marino, Contract Specialist. All questions must be in writing and can be faxed to 301-402-4513 or sent via email to marinome@mail.nih.gov. It is the vendor's responsibility to ensure questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must be registered in and have valid certifications in the Central Contractor Registration (CCR), www.ccr.gov and the Online Representations and Certifications Application (ORCA) www.orca.bpn.gov. Please reference NCI-90201-MM on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-90201-MM/listing.html)
- Record
- SN01920842-W 20090822/090821002229-0ea470367bfd07dd37b1348fe2d27880 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |